GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » ROE % Adjusted to Book Value

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co ROE % Adjusted to Book Value?

JW (Cayman) Therapeutics Co's ROE % for the quarter that ended in Dec. 2023 was 0.00%. JW (Cayman) Therapeutics Co's PB Ratio for the quarter that ended in Dec. 2023 was 0.47. JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 0.00%.


JW (Cayman) Therapeutics Co ROE % Adjusted to Book Value Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co ROE % Adjusted to Book Value Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - -12.38 -51.30 -79.81

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -15.35 -29.26 -53.98 -64.19 -

Competitive Comparison of JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value falls into.



JW (Cayman) Therapeutics Co ROE % Adjusted to Book Value Calculation

JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-37.51% / 0.47
=-79.81%

JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 0.47
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW (Cayman) Therapeutics Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines